Rixubis Kit
Product Images NDC 0944-3028

Product Visual Gallery

This gallery contains 32 technical images submitted to the FDA as part of the official labeling for Rixubis (NDC 0944-3028). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Rixubis 01)

An illustration showing a transparent plastic component partially covered by a peel-back protective film, with an arrow indicating the direction to peel the film off. This diagram likely depicts the opening or assembly step of a medical or pharmaceutical kit, such as the RIXUBIS coagulation factor IX recombinant kit.*

FDA Label Image

Figure B (Rixubis 02)

An instructional illustration showing two glass vials positioned beneath a plastic vial adapter with arrows indicating the process of attaching the adapter securely onto the vials, likely for reconstitution or mixing of medication components.*

FDA Label Image

Figure C (Rixubis 03)

Instructional diagram showing the preparation of a medication kit, including two vials and arrows indicating disassembly or movement for mixing or reconstitution steps. The image depicts vial with a cap and a vial with an attached mixing device.*

FDA Label Image

Figure D (Rixubis 04)

An instructional diagram showing a step in the preparation or assembly of a medication kit. It depicts a vial or container being inserted into or connected with another component, indicating the direction with a downward arrow.*

FDA Label Image

Figure E (Rixubis 05)

Illustrative diagram showing a two-step process involving a syringe. Step 1 indicates attaching a small vial or component to the syringe. Step 2 shows rotating or twisting the syringe barrel, possibly to mix or prepare the medication. No text other than numerical step indicators is visible.*

FDA Label Image

Figure F (Rixubis 06)

An instructional diagram showing the assembly of a syringe with two vial stoppers connected at the top, with an arrow indicating the direction to push the syringe plunger. This likely relates to the preparation or reconstitution process for the RIXUBIS kit.*

FDA Label Image

Image (Rixubis 07)

FDA Label Image

Image (Rixubis 08)

FDA Label Image

Image (Rixubis 09)

FDA Label Image

Image (Rixubis 10)

FDA Label Image

Image (Rixubis 11)

FDA Label Image

Figure (Rixubis 12)

An illustration showing a gloved hand holding a vial labeled RIXUBIS, with an arrow pointing to the vial cap being lifted or removed, indicating how to open the vial as part of preparation for use.*

FDA Label Image

Figure (Rixubis 13)

An instructional illustration showing two vials side by side. The left vial is sealed with a gray flip-off cap. The right vial is open, with a perforated protective seal being removed by a gloved hand, revealing a blue stopper beneath. The image appears to demonstrate vial preparation steps, typically associated with pharmaceutical kits such as RIXUBIS coagulation factor IX (recombinant).*

FDA Label Image

Figure (Rixubis 14)

An instructional illustration showing a partially peeled-back sterile film covering a transparent round medical device or component inside clear packaging. An arrow indicates the peeling direction, suggesting a step in product preparation or aseptic access, likely part of the RIXUBIS coagulation factor IX recombinant kit.*

FDA Label Image

Figure (Rixubis 15)

An instructional diagram illustrating how to assemble and align a vial adapter over two vials. The images show the vial adapter being positioned above each vial with arrows indicating the downward motion to secure it in place. This diagram is likely part of the preparation steps for the RIXUBIS coagulation factor IX (recombinant) kit by Takeda Pharmaceuticals America, Inc.*

FDA Label Image

Figure (Rixubis 16)

An instructional diagram showing a two-piece assembly process, where a container with a hinged cap is positioned above a vial. An arrow indicates the container should be pressed down onto the vial, implying an attachment or mixing step.*

FDA Label Image

Figure (Rixubis 17)

An instructional illustration showing the steps to open a medication vial kit, featuring a flip-top component over the vial and a hand manipulating the flip-top. The image likely demonstrates proper handling or preparation of the medication kit.*

FDA Label Image

Figure (Rixubis 18)

Instructional diagram showing steps for using a syringe with a vial adapter. Step 1 depicts removing a cap from the vial adapter, and step 2 shows rotating the syringe plunger to draw liquid into the syringe.*

FDA Label Image

Figure (Rixubis 19)

An instructional diagram showing a syringe attached to a vial adapter, with an arrow indicating the direction to pull or push, likely demonstrating the preparation or mixing step for RIXUBIS (Coagulation Factor IX Recombinant) Kit by Takeda Pharmaceuticals America, Inc.*

FDA Label Image

Figure (Rixubis 20)

An illustration showing a gloved hand applying a small adhesive bandage to the inside of a person's arm after drawing blood, which is secured with a tourniquet. The image depicts a typical post-blood draw care step.*

FDA Label Image

Figure (Rixubis 21)

An illustration showing hands wearing gloves administering an intravenous (IV) infusion through a needle inserted into an arm vein, connected by tubing to a syringe or infusion device. This diagram depicts the process of IV drug administration.*

FDA Label Image

Principal Display Panel (Kit Carton)

RIXUBIS Coagulation Factor IX (Recombinant) kit packaging label showing single-dose vial of lyophilized powder for solution, NDC 0944-3026-02. The label includes usage instructions for intravenous use after reconstitution and contents details such as one vial of dried Coagulation Factor IX, sterile water, and a BAXJECT II Needleless Transfer Device. Manufacturer listed as Takeda Pharmaceuticals America, Inc. Storage information and usage warnings are also provided.*

FDA Label Image

Principal Display Panel (5 mL Vial Label)

Label for RIXUBIS, coagulation factor IX (recombinant), a plasma derivative kit by Takeda Pharmaceuticals America, Inc. The label includes the NDC 0944-3025-01, dosage form as a kit, and instructions for intravenous use only. It also notes the product is not made with natural rubber latex and references the package insert for directions.*

FDA Label Image

Principal Display Panel (Kit Carton)

RIXUBIS Coagulation Factor IX (Recombinant) kit packaging label by Takeda Pharmaceuticals America, Inc. It shows a single-dose vial of lyophilized powder for solution, along with 5 mL sterile water for injection and a BAXJECT II Needleless Transfer Device. The label includes storage instructions, ingredients of the reconstituted product, and manufacturer information.*

FDA Label Image

Principal Display Panel (5 mL Vial Label)

RIXUBIS Kit label for Coagulation Factor IX (Recombinant) by Takeda Pharmaceuticals America, Inc. The label includes a warning for intravenous use only. It specifies no natural rubber latex in the product and references a package insert for directions. The label shows NDC 0944-3027-01 and includes spaces for IU, lot, and expiration date.*

FDA Label Image

Principal Display Panel (Kit Carton)

Packaging label for RIXUBIS COAGULATION FACTOR IX (RECOMBINANT) single-dose vial kit containing lyophilized powder for solution. The label indicates it is for intravenous use after reconstitution and includes a 5 mL vial. The kit contains one vial of dried factor IX, one vial with 5 mL sterile water for injection, one BAXJECT II needleless transfer device, and one package insert. Manufactured by Shire, a Takeda company.*

FDA Label Image

Principal Display Panel (5 mL Vial Label)

Label for RIXUBIS COAGULATION FACTOR IX (RECOMBINANT) KIT by Takeda Pharmaceuticals America, Inc. The label includes the NDC number 0944-3029-01, usage directions noting 'For Intravenous Use Only,' lot and expiration date fields, and states it is not made with natural rubber latex. Manufacturer information for Baxalta US Inc. in Lexington, MA is also visible.*

FDA Label Image

Principal Display Panel (Kit Carton)

Label for RIXUBIS Coagulation Factor IX (Recombinant) single-dose vial kit by Takeda Pharmaceuticals America, Inc. The label indicates lyophilized powder for solution with a 5 mL vial for injection. The kit includes sterile, nonpyrogenic components with no preservatives. Storage instructions advise refrigeration or room temperature up to 36 months without freezing.*

FDA Label Image

Principal Display Panel (5 mL Vial Label)

RIXUBIS kit packaging label for Coagulation Factor IX (Recombinant) by Takeda Pharmaceuticals America, Inc. The label indicates the product is for intravenous use only and is an Rx-only plasma derivative. It includes spaces for IU, lot number, and expiration date, with directions to see the package insert.*

FDA Label Image

Principal Display Panel (Kit Carton)

RIXUBIS [Coagulation Factor IX (Recombinant)] single-dose vial kit packaging label. The label includes the NDC 0944-3034-02, identifies lyophilized powder for solution, and specifies use for intravenous administration after reconstitution. It notes contents including one vial of the product, sterile water for injection, and a needleless transfer device. The label also provides storage instructions, manufacturer info (Takeda Pharmaceuticals America, Inc. under the Shire brand), and batch details.*

FDA Label Image

Principal Display Panel (5 mL Vial Label)

RIXUBIS [Coagulation Factor IX (Recombinant)] label from Takeda Pharmaceuticals America, Inc., designed for intravenous use only. The label includes a note to see the package insert for directions, stating the product is not made with natural rubber latex. The label features the NDC 0944-3033-01 and space for IU, Lot, and Expiration information.*

FDA Label Image

Principal Display Panel (5 mL Vial Label)

Label for Sterile Water for Injection, USP, 5 mL single dose container manufactured by Siegfried Hameln GmbH and distributed by BAXARTA US Inc. The label includes usage instructions for reconstitution, cautions against antimicrobial additives, and indicates the product is nonpyrogenic. Includes NDC 52919-003-08 and barcode for UCC/EAN code 005329 9003086.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.